Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (11190)	11/15/1997 6:46:00 PM
From: JOHN W.	Read Replies (4) \| Respond to of 32384

Yet there is still common sense in investing. Anyone can look at you chart to see that this company has gone no where since they were offered. 10-14 bucks is what this company has been trading in since its initial offereing. With all the news that recently has come out about LGND, and since I will assume it is all positive since I dont have a clue on biotechs and science, WHEN WILL SOMEONE MAKE ANY MONEY ON THIS COMPANY who has held onto this stock for the last 3 years.. Does someone have to wait 3-4 yrs until they can get out of the red, before this stock moves? With all that you have done here, you haven't been able to move this company...the stock price speaks volumes on a low volume non profitable company.Where is the BREAKOUT?

To: Henry Niman who wrote (11190)	11/15/1997 6:56:00 PM
From: CYBERKEN	Read Replies (1) \| Respond to of 32384

When AMLN's trial results came out I sold. It wasn't because I thought that they couldn't get approval; but that pramlintide, once approved, would have a very difficult time showing patients and their doctors any real value for the money spent (there's that BUSINESS angle again!). Better trial results later could change that. Now, however, it looks like the news is getting worse for the next year or so. The point is that this is the typical risk in investing in biotech development companies. Even Ligand may see this at some point-though the difference is that they are much more diversified. The lesson here is that biotech investors who experience this have to accept it and just move on or one day they will lose their remaining capital. I don't understand what any of them gain by moving to other threads and bashing other investors. Despite the cost, the lesson learned from an AMLN is valuable and can make you a more successful investor-but only if you are open-minded enough to understand the lesson. FWIW-I think Ligand goes up from here, as the wash periods from October start to run out and last month's sellers start to buy back positions. Also, I still am convinced that this is a short-term bottom for the sector and we will see a rally in biotech very soon.